TY - JOUR
T1 - Fracture prediction with modified-FRAX in older HIV-infected and uninfected men
AU - Yin, Michael T.
AU - Shiau, Stephanie
AU - Rimland, David
AU - Gibert, Cynthia L.
AU - Bedimo, Roger J.
AU - Rodriguez-Barradas, Maria C.
AU - Harwood, Katherine
AU - Aschheim, Josh
AU - Justice, Amy C.
AU - Womack, Julie A.
N1 - Funding Information:
Supported by the National Institutes of Health: AHRQ (R01-HS018372), NIAAA (U24-AA020794, U01-AA020790, U01-AA020795, U01- AA020799, U24-AA022001, U24 AA022007, U10 AA013566- completed), NHLBI (R01-HL095136; R01-HL090342), NIAID (U01-A1069918), NIMH (P30-MH062294), NIDA (R01DA035616), NCI (R01 CA173754), as well as the Veterans Health Administration Office of Research and Development (VA REA 08-266, VA IRR Merit Award) and the Office of Academic Affiliations (Medical Informatics Fellowship). Additional funding from the National Institutes of Health included: NIAID (R01 AI096089, R01 HD073977) and NINR (K01 NR013437). Veterans Aging Cohort Study funded by the National Institute on Alcohol Abuse and Alcoholism (U10 AA 13566) and the VHA Public Health Strategic Health Core Group.
Publisher Copyright:
© 2016 Wolters Kluwer Health, Inc.
PY - 2016/8/15
Y1 - 2016/8/15
N2 - Background: FRAX is a validated, computer-based clinical fracture risk calculator that estimates the 10-year risk of major osteoporotic (clinical spine, forearm, hip, or shoulder) fracture, and hip fracture alone. It is widely used for decision making in fracture prevention, but it may underestimate the risk in HIV-infected individuals. Some experts recommend considering HIV as a cause of secondary osteoporosis when calculating FRAX in HIV-infected individuals. Methods: From the Veterans Aging Cohort Study Virtual Cohort, we included 24,451 HIV-infected and uninfected men aged 50-70 years with complete data in the year 2000 to approximate all but 2 factors (ie, history of secondary osteoporosis and parental hip fracture) for modified-FRAX calculation without bone density and 10-year observational data for incident fragility fracture. The accuracy of the modified-FRAX calculation was compared by the observed/estimated (O/E) ratios of fracture by HIV status. Results: The accuracy of modified-FRAX was less for HIV-infected [O/E 1.62, 95% confidence interval (CI) 1.45 to 1.81] than uninfected men (O/E 1.29, 95% CI: 1.19 to 1.40), but improved when HIV was included as a cause of secondary osteoporosis (O/E 1.20, 95% CI: 1.08 to 1.34). However, only 3%-6% of men with incident fractures were correctly identified by the modified-FRAX using accepted FRAX thresholds for pharmacologic therapy. Conclusions: Modified-FRAX underestimated the fracture rates more in older HIV-infected than in otherwise similar uninfected men. The accuracy improved when HIV was included as a cause of secondary osteoporosis, but it still performed poorly for case finding. Further studies are necessary to determine how to use FRAX or define an HIV-specific index to risk stratify for screening and treatment in older HIV-infected individuals.
AB - Background: FRAX is a validated, computer-based clinical fracture risk calculator that estimates the 10-year risk of major osteoporotic (clinical spine, forearm, hip, or shoulder) fracture, and hip fracture alone. It is widely used for decision making in fracture prevention, but it may underestimate the risk in HIV-infected individuals. Some experts recommend considering HIV as a cause of secondary osteoporosis when calculating FRAX in HIV-infected individuals. Methods: From the Veterans Aging Cohort Study Virtual Cohort, we included 24,451 HIV-infected and uninfected men aged 50-70 years with complete data in the year 2000 to approximate all but 2 factors (ie, history of secondary osteoporosis and parental hip fracture) for modified-FRAX calculation without bone density and 10-year observational data for incident fragility fracture. The accuracy of the modified-FRAX calculation was compared by the observed/estimated (O/E) ratios of fracture by HIV status. Results: The accuracy of modified-FRAX was less for HIV-infected [O/E 1.62, 95% confidence interval (CI) 1.45 to 1.81] than uninfected men (O/E 1.29, 95% CI: 1.19 to 1.40), but improved when HIV was included as a cause of secondary osteoporosis (O/E 1.20, 95% CI: 1.08 to 1.34). However, only 3%-6% of men with incident fractures were correctly identified by the modified-FRAX using accepted FRAX thresholds for pharmacologic therapy. Conclusions: Modified-FRAX underestimated the fracture rates more in older HIV-infected than in otherwise similar uninfected men. The accuracy improved when HIV was included as a cause of secondary osteoporosis, but it still performed poorly for case finding. Further studies are necessary to determine how to use FRAX or define an HIV-specific index to risk stratify for screening and treatment in older HIV-infected individuals.
KW - FRAX
KW - HIV
KW - fracture incidence
KW - men
UR - http://www.scopus.com/inward/record.url?scp=84961392325&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961392325&partnerID=8YFLogxK
U2 - 10.1097/QAI.0000000000000998
DO - 10.1097/QAI.0000000000000998
M3 - Article
C2 - 27003493
AN - SCOPUS:84961392325
SN - 1525-4135
VL - 72
SP - 513
EP - 520
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
IS - 5
ER -